ONCOLOGY
31 Dec 2020
31 Dec 2020
31 Dec 2020
31 Dec 2020
30 Dec 2020
22 Nov 2020
31 Aug 2020
31 Aug 2020
31 Aug 2020
30 Jun 2020
Expert Insight View All
Conference update View All
Meeting Highlight View All
The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival
31 Aug 2020
Case review View All
News & perspective View All
Infographics View All
Features View All
First-line treatment with immunotherapy in metastatic squamous NSCLC
Immunotherapy has dramatically changed the therapeutic scenario in the treatment-naïve advanced NSCLC. While the single agent pembrolizumab has become the standard first-line therapy in patients with ≥50% PD-L1 expression on tumor cells,
31 Aug 2020